RZLT
Rezolute, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.70
+3.35%Oct 14, 2026, 20:05 UTC
Rezolute announced that enrollment is complete in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism, with topline results expected in mid-December 2026.
Source:Oct 5, 2026, 11:00 UTC
The FDA recommended holding a pre-BLA meeting with Rezolute as a precursor to submitting a Biologics License Application for congenital hyperinsulinism.
Source:Sep 24, 2026, 20:05 UTC
Rezolute, Inc. reported its financial results for the fourth quarter and full fiscal year ended June 30, 2026.
Source:Aug 25, 2026, 07:52 UTC
Bank of America Corp DE reduced its stake in Rezolute, Inc. by 31.3% during the quarter, selling 1,354,699 shares, according to its Form 13F filing.
Source:Jun 2, 2026, 16:31 UTC
Rezolute, Inc. reported an interim update from its ongoing Phase 3 upLIFT study evaluating ersodetug in patients with tumor hyperinsulinism.
Source: